Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis
Interstitial Cystitis
About this trial
This is an interventional treatment trial for Interstitial Cystitis focused on measuring Post-operative pain management, Pain Management, Painful bladder syndrome, frequency and urgency, Dexmedetomidine, hydrodistension
Eligibility Criteria
Inclusion Criteria:
- Patients with a clinical diagnosis of IC scheduled for cystoscopy and hydrodistension for both diagnostic and therapeutic indications.
- 2. Gender of Patients: Male & female,Age of Patients: 18 and older
Exclusion Criteria:
- Conduction disturbance (second degree AV block or greater), or previous reaction to medications used in this study. Patients receiving spinal anesthesia will not be included.
Sites / Locations
- University of Rochester Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Dexmedetomidine
Normal Saline
Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.